Clinigen establishes first Chinese mainland subsidiary in Shanghai's Waigaoqiao

Clinigen is a globally recognized pharmaceutical service provider. [Photo/pdnews]

Clinigen, a global specialist pharmaceutical services and products company headquartered in the United Kingdom, recently established its wholly-owned subsidiary in Shanghai's Waigaoqiao area, the first of its kind on the Chinese mainland.

The company will leverage the preferential policies offered by the local free trade zone in customs, investment, and cross-border financing to establish a comprehensive pharmaceutical service platform that connects the Chinese market with the rest of the world.

Clinigen excels at navigating complexity and accelerating access to medicines to those who need them, whether in clinical trials, early access programs, or long-term commercialization (licensed and unlicensed pathways). Over the past three years, the company has provided licensed drug supply services to 128 countries, covering over 1,500 innovative drugs.

With over 1200 employees in 14 countries, it has established close collaborations with 34 top 50 global pharmaceutical companies and is closely connected to over 5,000 hospitals in 115 countries.

Waigaoqiao's biopharmaceutical sector, which has attracted over 800 biopharmaceutical companies, provides a high-quality business environment for enterprises, forming an industrial ecosystem with the aggregation of leading enterprises and an accelerated layout of innovative businesses. Clinigen's entry further expands the "circle of friends" in Waigaoqiao's biopharmaceutical industry.